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Repurposing Drugs: A therapeutic option to control the
outbreak of new infective pathogens
Binita Dutta1, Ankita Menon2, Pradeep M Muragundi2*
Email: pradeep.mm@manipal.edu

Abstract
There has been limited development, approval and manufacturing of new medicines for the chemotherapeutic
intervention of diseases caused by viral infections. The limited development could be due to multitudinous
reasons such as a sudden outbreak of pathogenic microorganism, or a lack of financial incentives by the industry
to invest in development and clinical trials. Drug repurposing (DR) is one of the drug development strategies
adopted by the healthcare system to combat diseases caused by the sudden outbreak of pathogens characterized
by its pandemic potential or a rare form of cancer, for which there is no effective therapy available. However,
there are possible limitations to this strategy such as legal or regulatory barriers, intellectual property rights
linked to the original drug, an increase in the manufacturing capacity or a negative perception towards the use
of repurposed drugs by clinicians and patients. In this opinion paper, we have summarized the repositioning of
the off-label generic drugs as a possible therapeutic avenue to combat microbial infections such as the recent
outbreak of Coronavirus infection, COVID-19.
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Introduction
There has been limited development, approval
and manufacturing of new medicines for the
chemotherapeutic intervention of diseases caused by
viral infections. The limited development could be due
to multitudinous reasons such as a sudden outbreak
of pathogenic microorganism, a lack of financial
incentives by the industry to invest in development
and clinical trials. Drug repurposing (DR) is one
of the drug development strategies adopted by the
healthcare system to combat diseases caused by the
sudden outbreak of pathogens characterized by its
pandemic potential or a rare form of cancer, for
which there is no effective therapy available.1 In DR,
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an existing well-characterized clinically approved
drug could be used in such cases by exploring a
new mechanism of actions, new indications or new
targets for the intervention. Additionally, the chances
of repurposed drugs to fail are lower than the novel
drug due to the availability of pre-clinical and
clinical data of the original off-patent and off-label
drugs. Hence, repurposed drugs require a shorter
clinical trial and abbreviated regulatory approval.
This approach of drug repositioning could be a
time and cost effective alternative to a traditional
drug discovery process.2 These drugs could also be
allowed for the compassionate use due to the lack of
an effective treatment to circumvent sudden outbreak
of diseases. However, there are possible limitations
to this strategy such as legal or regulatory barriers,
intellectual property rights linked to the original
drug, an increase in the manufacturing capacity or a
negative perception towards the use of repurposed
drugs by clinicians and patients. In this opinion paper,
we have summarized the repositioning of the offlabel generic drugs as a possible therapeutic avenue
to combat microbial infections such as the recent

How to cite this article: Dutta B, Menon A,Muragundi P M. Repurposing Drugs: A therapeutic option to control the outbreak
of new infective pathogens. MJPS 2020; 6(2): 105-108.

Manipal Journal of Pharmaceutical Sciences | September 2020 | Volume 6 | Issue 2

105

